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Abstract
Background: Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) is a poorly understood disease with no
known treatments. We describe the clinical features and treatment outcomes of patients with laboratory confirmed
MERS-CoV at a regional referral center in the Kingdom of Saudi Arabia.
Methods: In 2014, a retrospective chart review was performed on patients with a laboratory confirmed diagnosis of
MERS-CoV to determine clinical and treatment characteristics associated with death. Confounding was evaluated
and a multivariate logistic regression was performed to assess the independent effect of treatments administered.
Results: Fifty-one patients had an overall mortality of 37 %. Most patients were male (78 %) with a mean age of
54 years. Almost a quarter of the patients were healthcare workers (23.5 %) and 41 % had a known exposure to
another person with MERS-CoV. Survival was associated with male gender, working as a healthcare worker, history
of hypertension, vomiting on admission, elevated respiratory rate, abnormal lung exam, elevated alanine
transaminase (ALT), clearance of MERS-CoV on repeat PCR polymerase chain reaction (PCR) testing, and
mycophenolate mofetil treatment. Survival was reduced in the presence of coronary artery disease, hypotension,
hypoxemia, CXR (chest X-ray) abnormalities, leukocytosis, creatinine >1 · 5 mg/dL, thrombocytopenia, anemia, and
renal failure. In a multivariate analysis of treatments administered, severity of illness was the greatest predictor of
reduced survival.
Conclusions: Care for patients with MERS-CoV remains a challenge. In this retrospective cohort, interferon beta and
mycophenolate mofetil treatment were predictors of increased survival in the univariate analysis. Severity of illness
was the greatest predictor of reduced survival in the multivariate analysis. Larger randomized trials are needed to
better evaluate the efficacy of these treatment regimens for MERS-CoV.
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Background
Coronaviruses cause a spectrum of illness from asymp-
tomatic disease to respiratory failure. Early reports of
coronavirus infections suggested that most infections
were mild until the 2003 SARS epidemic that was asso-
ciated with significant morbidity and mortality [1]. In
September 2012, a novel coronavirus was identified in a
60-year old man in Saudi Arabia [2]. A second case was
identified in a Qatari patient hospitalized in the United
Kingdom [3]. The two coronaviruses were genetically
identical and similar to isolates obtained from bats [4].
In July 2013, the coronavirus study group named this
new virus Middle East respiratory syndrome coronavirus
(MERS–CoV) [5].
As of December 21, 2015, there have been 1625 cases
worldwide with 586 deaths [6]. The epidemiology and
clinical manifestations of this disease have described a
spectrum of illness from asymptomatic infection to se-
vere respiratory failure and death. The overall mortality
rate remains at 37 % [7–15]. Importantly, there are no
known effective treatments. In 2014 there was an in-
crease in MERS-CoV cases reported from the Jeddah re-
gion of Saudi Arabia. To describe the changing
epidemiology and outcomes, we report the clinical fea-
tures and treatment outcomes of patients admitted to a
regional referral hospital in Jeddah, Saudi Arabia.
Methods
Study setting and participants
King Fahd General Hospital is an 800-bed hospital
in Jeddah, Kingdom of Saudi Arabia and is a re-
gional coronavirus referral center. There are 36 ICU
beds and one Infectious Disease physician that
serves the hospital. Between January through December
2014, all patients admitted or transferred to King
Fahd Hospital with a positive MERS coronavirus PCR
from clinical nasal swabs or nasopharyngeal aspirates
were included.
Molecular methods
All PCR testing was performed at the Ministry of Health
Regional Lab in Jeddah. The MagNa Pure Compact/
MagNa Pure 96 (Roche) automated system was used to
extract RNA from samples. Primers and probes for upE
and Orf 1a targets of MERS-CoV were used from TIB
MOLBIOL (Germany) along with Master Mix from
Roche for the Light Cycler 480 II (Roche) were used to
amplify upE and Orf 1a gene targets. Samples that tested
positive for both upE and Orf 1a gene targets with a
cycle threshold time of less than 37 were considered
confirmed cases. Positive and negative controls were
used to monitor the amplification process & to check
for any inhibition of amplification.
Case review and definitions
Medical charts for all patients were reviewed and data
abstracted on standardized data collection forms by an
infectious disease trained physician. Demographic, clin-
ical and laboratory data were entered into a database.
To understand the epidemiology, age was categorized
as <30, 30–60 and >60. Hypotension was defined as
blood pressure <90/60 mm Hg, tachypnea as a respira-
tory rate greater than 16, hypoxia as an oxygen satur-
ation <90 %, thrombocytopenia as platelets <150,000/
cubic millimeter, leukopenia was defined as a white
blood cell count <5000 cells/cubic millimeter and
leukocytosis as a white blood cell count >10,000 cells/
cubic millimeter. Renal insufficiency was defined as a
creatinine >1.5 mg/dL. Liver function abnormalities
were defined as a lactate dehydrogenase (LDH) >300
U/liter, alanine transaminase (ALT) > 50 U/Liter and
aspartate aminotransferase (AST) >40 U/Liter. Im-
munosuppression was defined as AIDS, history of organ
transplant, neutropenia, known malignancy, taking im-
munosuppressive medication and congenital immunodefi-
ciency. Pregnancy was considered an immunosuppressed
state.
A modified Acute Physiologic and Chronic Health
Evaluation (APACHE 2) score was calculated using age,
temperature, mean arterial blood pressure, respiratory
rate, potassium, creatinine, acute renal failure, and co-
morbid conditions to estimate severity of illness [16].
PaO2 was estimated using pulse oximetry oxygen satur-
ation results and hematocrit was calculated by multiply-
ing the hemoglobin times three.
Statistical analysis
All statistical analyses were performed using Stata soft-
ware (Version 13.1, College Station, TX). The percent
distribution of clinical variables among patients who sur-
vived and those who died were compared using the
Fisher exact test. A multivariate logistic regression was
done on treatments administered and severity of illness
to determine which treatments were associated with sur-
vival. Mycophenolate mofetil was not included in this lo-
gistic regression analysis because 100 % of patients
receiving mycophenolate mofetil survived. The associ-
ation between severity of illness and treatments adminis-
tered was assessed by performing a linear regression of
treatments administered onto the modified APACHE 2
score.
Results
Demographic and exposure characteristics
There were a total of 51 cases, thirty patients (58.8 %) of
whom were Saudi nationals, and 21 (41.2 %) were for-
eign nationals. The median age was 54 years old (IQR
36.5–58). Most were male (n = 40, 78.4 %). Twenty-one
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patients (41.2 %) had exposure to a known patient with
MERS coronavirus and 12 (23.5 %) were healthcare
workers. None of the patients had animal exposure. Two
patients (3.9 %) were on pilgrimage to Mecca.
Overall, 71 % of patient had at least one co-morbid
condition. Seventeen patients had diabetes (33.3 %), 25
had hypertension (49 %), 14 (27.5 %) had end stage renal
disease, eight (15.7 %) had coronary artery disease and
six (11.8 %) patients were immunosuppressed, two of
whom were pregnant.
Clinical and laboratory findings
Forty-nine patients (96 %) had documented fever, 41
(80.4 %) had cough, and 46 (90 %) reported shortness of
breath. Thirteen patients (25.5 %) had diarrhea, 12
(23.5 %) had vomiting and 5 (9.8 %) complained of sore
throat. The clinical findings on presentation included
eight patients (15.7 %) with hypotension, 39 (76.9 %)
with tachypnea and 17 patients (33 %) with hypoxia. As
previously reported, laboratory findings were non-
specific. Fourteen patients (27.5 %) were anemic, 15
(29.4 %) were thrombocytopenic, and 28 (54.9 %) were
leukopenic. Many patients had liver function abnormal-
ities. Twenty-three (45.1 %) had elevated ALT and 35
(68.6 %) had an elevated AST. Thirty-two patients
(62.8 %) had an elevated LDH, 24 patients (47.1 %) had
an elevated CK and 21 patients (41.2 %) had an elevated
creatinine.
Treatments administered
Patients received a variety of novel treatments including
immunosuppressants and antivirals. Forty-two (82.4 %)
patients received broad-spectrum antibiotics and five
(9.8 %) received hydrocortisone. Thirty one patients
received antiviral treatment. Twenty-three patients
(45.1 %) were treated with interferon beta, eight (15.7 %)
were treated with interferon alpha. A variety of anti-viral
combinations were used. Eight patients (15.7 %) received
mycophenolate mofetil, seven of these patients received
it in combination with interferon beta. Nineteen (37.3 %)
patients required intensive care unit (ICU) care, and 10
patients received extracorporeal membrane oxygenation
(ECMO). All patients treated in the ICU and all patients
receiving ECMO died.
Univariable association of demographic, clinical features
and treatment with death
In this recent cohort, when comparing survivors to non-
survivors, survival was associated with male gender,
vomiting on admission, elevated respiratory rate, abnor-
mal lung exam on physical exam, working as a healthcare
worker, history of hypertension, elevated ALT, clearance
of MERS CoV on repeat PCR testing, and receiving myco-
phenolate mofetil or beta interferon (Table 1). In contrast,
markers of severe disease like hypotension, hypoxemia,
chest radiographic abnormalities, leukocytosis, elevated
creatinine, thrombocytopenia, anemia, renal failure were
associated with death.
Treatments given
Treatments given were based as indicated based on the
clinical assessment of the infectious disease consult
team. Thirty-one patients received antivirals, ribavirin or
alpha or beta interferon, and 13 patients received im-
munosuppressive medication. Most patients received a
combination of alpha interferon and ribavirin (5, 9.8 %),
beta interferon and ribavirin (10, 19.5 %) or beta inter-
feron alone (11, 21.6 %). Two patients received alpha
interferon alone (3.9 %). Eight patients received myco-
phenolate mofetil (15.7 %) and seven of them received
this in combination with beta-interferon. Five patients
received hydrocortisone; two in combination with beta
interferon and ribavirin and 3 in combination with alpha
interferon and ribavirin. All eight patients given myco-
phenolate mofetil survived therefore mycophenolate mo-
fetil could not be evaluated in this model.
Impact of treatments
While the results of the univariable analysis demon-
strated improved survival in patients treated with beta-
interferon and mycophenolate mofetil, the multivariable
analysis which included a marker of severity of illness,
demonstrated a strong association between severity of
illness and reduced survival, and no association between
treatment with beta interferon and survival. Mycopheno-
late mofetil was not evaluable in this model (Table 2). In
analyzing the relationship between severity of illness and
treatments administered, beta interferon and mycophe-
nolate mofetil were given to less severely ill patients
(Table 3)
Discussion
MERS-CoV is an emerging disease for which the initial
epidemiology has been described, but in-depth clinical
studies and the role of therapy in incompletely under-
stood. While the clinical features for MERS-CoV have
been described in several large case series [6–14], there
is a paucity of literature on therapy. Our results from a
relatively large number of patients demonstrate similar
clinical features and mortality to previous studies [6–14].
In our cohort, treatment with beta interferon and myco-
phenolate mofetil may be predictive of survival, but the
greatest predictor of survival is the severity of illness on
presentation.
Improved diagnostics have demonstrated an expanded
spectrum of disease that includes less severe cases than
previously reported. We now understand that MERS-
CoV causes an acute respiratory disease syndrome and
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Table 1 Predictors for poor outcome among 51 MERS CoV cases in KSA 2014
Total Survival Death P value
Demographics and Epidemiology
Age < = 30 7 (13.7 %) 6 (85.7 %) 1 (14.29 %) 0.187
Age 31-60 32 (62.8 %) 22 (64.7 %) 12 (35.3 %)
Age >60 10 (19.6 %) 4 (40 %) 6 (60 %)
Gender - male 40 (78.4 %) 22(55 %) 18(45 %) 0.037
Known MERS exposure 21 (41.2 %) 12 (57.1 %) 9 (42.9 %) 0.563
Healthcare worker 12 (23.5 %) 11 (91.7 %) 1 (8.3 %) 0.020
Umrah patient 2 (3.9 %) 2 (100 %) 0 (0 %) 0.523
Co-morbid conditions
Diabetes 17 (33.3 %) 9 (52.9 %) 8 (47.1 %) 0.365
Hypertension 25 (49 %) 10 (40 %) 15 (60 %) 0.001
End stage renal disease 14 (27.5 %) 6 (42.9 %) 8 (57.1 %) 0.106
Coronary artery disease 8 (15.7 %) 3 (37.5 %) 5 (62.5 %) 0.131
Immunosuppression 6 (11.8 %) 5 (83.3 %) 1 (16.7 %) 0.392
Signs and Symptoms
Runny nose 6 (11.8 %) 5 (83.3 %) 1 (16.67 %) 0.392
Cough 41(80.4 %) 26 (63.4 %) 15(36.6 %) 1.000
Diarrhea 13 (25.5 %) 11 (84.6 %) 2 (15.4 %) 0.096
Vomiting 12 (23.5 %) 11 (91.7 %) 1 (8.3 %) 0.020
Sore throat 5 (9.8 %) 3 (60 %) 2 (40 %) 1.000
Abnormal lung exam 20 (39.2 %) 17 (85 %) 3 (15 %) 0.016
Subjective fever 49 (96.1 %) 30 (61.2 %) 19 (38.8 %) 0.523
Temperature >38 Celsius 25 (49 %) 13 (52 %) 12 (48 %) 0.153
Respiratory rate >16 39 (76.5 %) 21 (53.9 %) 18 (46.2 %) 0.020
Blood pressure < 90/60 mm Hg 8 (15.7 %) 0 (0 %) 8 (100 %) 0.000
Oxygen saturation < 90 % 17 (33.3 %) 4 (23.5 %) 13 (76.5 %) 0.000
Laboratory findings
Hemoglobin < 10 g/dL 14 (27.5 %) 4 (28.6 %) 10 (71.4 %) 0.003
White Blood cell count < 5,000 cells/mm3 28 (54.9 %) 21 (75 %) 7 (25 %) 0.080
White Blood cell count > 10,000 cells/mm3 9 (17.6 %) 2 (22.2 %) 7 (77.8 %) 0.009
Platelets < 150,000/mm3 15 (29.4 %) 9 (60 %) 6 (40 %) 1.000
ALT > 50 U/L 23 (45.1 %) 14 (61 %) 9 (39.1 %) 1.000
AST > 40 U/L 35 (68.6 %) 18 (51.4 %) 17 (48.6 %) 0.015
LDH > 300 U/L 32 (62.7 %) 18 (56.3 %) 14 (43.8 %) 0.247
Creatinine > 1.5 mg/dL 21 (41.2 %) 8 (38.1 %) 13 (61.9 %) 0.003
CK > 200 U/L 24 (47.1 %) 13 (54.2 %) 11 (45.8 %) 0.261
Potassium > 4.5 mmol/L 17 (33.3 %) 8 (47.1 %) 9 (52.9 %) 0.131
Negative repeat PCR swab 31 (60.8 %) 30 (96.8 %) 1 (3.23 %) 0.000
Radiology
CXR – Right upper lobe infiltrate 17 (33.3 %) 5 (29.4 %) 12 (70.6 %) 0.001
CXR – Right lower lobe infiltrate 32 (62.7 %) 13 (40.6 %) 19 (59.4 %) 0.000
CXR – Left upper lobe infiltrate 19 (37.3 %) 7 (36.8 %) 12 (63.2 %) 0.006
CXR – Left lower lobe infiltrate 31 (60.8 %) 13 (41.9 %) 18 (58.1 %) 0.000
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one third of patients present with gastrointestinal symp-
toms [14]. Fever has been seen in 62–87 % of patients,
cough in 55–87 %, and gastrointestinal symptoms in
26–35 %. Seventy-six to 96 % percent of patients have
had comorbid illnesses, most commonly chronic renal
failure, diabetes and heart disease [7–15]. This may be
partially related to the epidemiology of increased disease
transmission in healthcare settings rather than a true
host risk factor. Laboratory findings have been non-
specific and consistent with other viral infections.
Thrombocytopenia (75 %) and lymphopenia (58 %) have
been commonly described in these patients [7, 9–13, 15].
Forty three percent had acute kidney injury [7, 11–13, 17]
and 76–100 % had CXR abnormalities with bibasilar infil-
trates as the most common finding [8–13, 15, 18]. The
outcomes in these more severely ill patients remain poor.
Between 50–90 % required ICU care [10, 11, 13, 15] and
67–100 % in the ICU setting required invasive ventilation
for a median of 7–16 days [8, 10, 12]. In addition to mech-
anical ventilation, several patients have received extra-
corpeal membrane oxygenation (ECMO) to support
ventilation. From non-randomized data from the World
Health Organization, five out of six patients receiving
ECMO died [9]. Fifty-eight to 75 % required renal replace-
ment therapy [11, 12, 17] and 30–60 % of hospitalized pa-
tients died [7–15]. The severity of illness can be partially
explained by the widespread lung disease caused by
MERS-CoV and it appears that mortality in those patients
requiring intensive care is extremely high. Although no
autopsy data is available, in explanted lung, infection with
MERS-CoV causes widespread infection and alveolar dis-
ease [19, 20].
The clinical features in our cohort similarly also show
a high proportion of patients with fever (96 %) and
cough (80.4 %) shortness of breath (90 %), and almost
one third of patients (29.4 %) with gastrointestinal symp-
toms. Our cohort consisted of ill patients with
hypotension (15.7 %), tachypnea (76.9 %) and hypoxia
(33 %). Thirty seven percent required ICU care and 10
patients received ECMO. Similar to previous results, all
of the patients who received ECMO died [9].
There is no known effective treatment for MERS CoV.
Many compounds have been screened in vitro for pos-
sible activity against this coronavirus [21–24], however,
the in vivo efficacy has not been subjected to clinical
investigation.
In vitro data suggests that MERS-CoV inhibits host
interferon production through various molecular path-
ways [25–30] mycophenic acid, the active agent of pro-
drug mycophenolate mofetil, and cyclosporine strongly
inhibit MERS coronavirus in human and monkey cell
lines even more so than they inhibit SARS coronavirus
[24, 31–33]. Interferon alpha and interferon beta reduce
MERS coronavirus replication in explanted lung tissue
[19]. In vivo, comparing host response in two patients
with MERS coronavirus and differing outcomes, the pa-
tient who was able to clear MERS CoV infection was
able to mount an interferon response and the patient
who died had low levels of interferon alpha suggesting a
Table 1 Predictors for poor outcome among 51 MERS CoV cases in KSA 2014 (Continued)
Treatments administered
Interferon beta 23 (45.1 %) 18 (78.3 %) 5 (21.7 %) 0.047
Interferon alpha 8 (15.7 %) 6 (75 %) 2 (25 %) 0.694
Any interferon 31 (60.8 %) 24 (77.4 %) 7 (22.6 %) 0.009
Ribavirin 19 (37.5 %) 13 (68.4 %) 6 (13.6 %) 0.564
Antibiotics 42 (82.4 %) 26 (61.9 %) 16 (38.1 %) 1.000
Hydrocortisone 5 (9.8 %) 2 (40 %) 3 (60 %) 0.348
Mycophenolate mofetil 8 (15.7 %) 8 (100 %) 0 (0 %) 0.019
ICU stay during admission 19 (37.3 %) 0 (0 %) 19 (100 %) 0.000
Extracorporeal Membrane Oxygenation 10 (19.6 %) 0 (0 %) 10 (100 %) 0.000
Table 2 Multivariable analysis of treatments and their impact
on mortality
Odds ratio Confidence interval P value
Beta interferon 0.68 0.04–10.28 0.778
Alpha interferon 0.47 0.02–10.38 0.630
Hydrocortisone 2.92 0.13–63.62 0.495
Ribavirin 0.66 0.04–12.36 0.779
Modified APACHE 2 score 1.60 1.18–2.17 0.002
Table 3 Univariable analysis of the impact of severity of illness
on treatments administered
Risk association Confidence interval P value
Beta interferon – 4.62 −8.40, −0.84 0.018
Alpha interferon – 1.24 −6.71, 4.24 0.652
Ribavirin 0.78 −3.34,4.90 0.704
Viral treatment – 5.98 −9.73, −2.23 0.002
Mycophenolate mofetil – 7.91 −12.90, −2.91 0.003
Hydrocortisone 3.03 −3.62,9.68 0.364
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therapeutic role for interferon [34]. The combination of
interferon alpha and ribavirin has been used successfully
in rhesus monkeys infected with MERS coronavirus [35],
and in a few small case series [36–38]. Beta-interferon
seems to be an even more potent inhibitor of MERS cor-
onavirus in vitro [19] [24, 31–33]. One small study with
exceptionally high mortality rates using interferon beta
for treatment found no difference in mortality between
interferon beta use and interferon alpha use [39]. Our
data, albeit from a retrospective cohort support the find-
ings that interferon beta is associated with a decrease in
mortality.
There are limited data on the efficacy of treatment
regiments for this virulent disease. We present data from
a retrospective cohort of ill patients with Mers-CoV and
the results of the evaluation of the clinical efficacy of
beta interferon beta, alpha interferon, ribavirin and my-
cophenolate mofetil in addition to routine supportive
care. Forty five percent of patents (23 patients) received
interferon beta and in this cohort, sixteen percent of pa-
tients received interferon alpha (8 patients) and 37 % of
patients (9 patients) received ribavirin, either in conjunc-
tion with interferon alpha or interferon beta, and 8 pa-
tient received mycophenolate mofetil. Patients receiving
beta interferon and mofetil had improved survival, how-
ever this was confounded by the severity of illness on
presentation for beta interferon. All of the patients who
received mycophenolate mofetil survived however be-
cause of the small number, we could not analyze the in-
dependent efficacy of mycophenolate mofetil.
While this is a relatively large series of MERS-CoV
cases, the primary limitation of our study is that it is a
retrospective review of cases and not a randomized trial
and thus subject to confounding as seen in our cohort.
We used a modified APACHE 2 score without all of the
clinical variables, which may have underestimated the
association of severity of illness with reduced survival.
Importantly, the mortality in patients receiving add-
itional therapies that modulate the immune response
was low. All of the eight patients who received myco-
phenolate mofetil in our study survived. Hence, it may
be reasonable to further study this agent in controlled
trials.
Conclusions
This observational study investigates novel treatment
options like beta interferon and mycophenolate mofetil
for MERS-CoV in humans which have in vitro activity.
Our cohort demonstrated severity of illness is an import-
ant effect modifier and needs to be considered in evalu-
ating novel agents. To better assess the efficacy of these
therapies, international prospective randomized trials
with adequate numbers of patients are needed to further
evaluate the impact of these treatments in addition to
routine supportive care when compared to other treat-
ment options.
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